BRAF and melanoma: Development of therapy targeting druggable mutations (potentially actionable with an already approved therapy) enables patients with these gene alterations to experience significantly improved clinical benefits compared to conventional therapy (e.g., targeting HER-2 overexpression in the breast or gastric cancer, BRAF V600E mutation in melanoma, EGFR or ALK in lung cancer) (2–4).